HOW SHOULD WE INTRODUCE HIGH-DOSE CHEMOTHERAPEUTIC STRATEGIES INTO THE ADJUVANT MANAGEMENT OF HIGH-RISK BREAST CANCER IN AUSTRALASIA?
- 21 January 1998
- journal article
- review article
- Published by Wiley in Anz Journal of Surgery
- Vol. 68 (1) , 10-15
- https://doi.org/10.1111/j.1445-2197.1998.tb04628.x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.Journal of Clinical Oncology, 1995
- High-dose chemotherapy for breast cancerCancer Treatment Reviews, 1995
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year resultsPublished by American Medical Association (AMA) ,1995
- Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.Journal of Clinical Oncology, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Postmastectomy radiotherapy in the management of operable breast cancerCancer, 1994
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) trialInternational Journal of Radiation Oncology*Biology*Physics, 1990